Showing results (101-110 of 141) with videos related to
Sort By:
Pageof 15
Bone Marrow Transplantation|January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMTMeral Beksac, Diderik-Jan Eikema, Linda Koster, et al.Thrombosis and Haemostasis|August 2, 2013
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugsXavier Leleu, Philippe Rodon, Cyrille Hulin, et al.Blood|November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorAnaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experienceHervé Avet-Loiseau, Cyrille Hulin, Loic Campion, et al.The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2017
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyPhilippe Moreau, Michel Attal, Denis Caillot, et al.The Lancet. Haematology|March 28, 2020
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trialMaria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et al.Annals of Hematology|January 14, 2018
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myelomaGuillemette Fouquet, Lionel Karlin, Margaret Macro, et al.Pageof 15